|
시장보고서
상품코드
2053099
Rnai 기술 시장 : 용도별, 최종사용자별, 지역별Rnai Technology Market, By Application, By End User, By Geography |
||||||
Rnai 기술 시장은 2026년에 35억 8,000만 달러로 추정되며, 2033년까지 96억 5,000만 달러에 달할 것으로 예상됩니다. 2026년부터 2033년까지 CAGR 15.2%로 성장할 것으로 전망됩니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도: | 2025년 | 2026년 시장 규모: | 35억 8,000만 달러 |
| 과거 데이터 기간: | 2020-2024년 | 예측 기간: | 2026-2033년 |
| 2026년부터 2033년까지 예측 기간 CAGR: | 15.20% | 2033년 시장 규모 예측: | 96억 5,000만 달러 |
세계 RNAi 기술 시장의 성장은 치료제 개발 및 연구개발에서 RNA 간섭 기술의 적용 확대에 의해 주도되고 있습니다. RNA 간섭(RNAi)은 짧은 간섭 RNA(siRNA) 또는 마이크로 RNA(miRNA)에 의해 매개되는 유전자 침묵화 과정을 말합니다. 이는 유전자 발현의 선택적 억제 및 기능적 유전체 스크리닝을 위한 강력한 도구로 부상하고 있습니다. RNAi는 특정 질병 원인 유전자를 침묵시킴으로써 새로운 치료제를 개발할 수 있는 무한한 가능성을 가지고 있습니다. 안전하고 효과적인 전달 시스템의 개발은 RNAi 기반 치료법의 상용화를 더욱 촉진하고 있습니다. 바이오제약 기업 및 정부기관의 RNAi 연구개발에 대한 막대한 투자로 강력한 제품 파이프라인이 형성되고 있습니다.
시장 역학
세계 RNAi 기술 시장의 성장은 치료 영역을 넘나들며 치료법을 개발하기 위한 RNAi 기술의 적용 확대에 의해 주도되고 있습니다. 현재 대사성 질환, 심혈관질환, 신경퇴행성 질환을 타겟으로 하는 여러 약물 후보물질이 임상시험 단계에 있습니다. 풍부한 제품 파이프라인과 새로운 RNAi 의약품의 등장으로 이 기술의 치료적 잠재력에 대한 기대가 높아지고 있습니다. 그러나 RNAi 전달의 기술적 문제나 표적 외 효과로 인해 시장 성장을 저해할 수 있습니다. 또한, 연구개발(R&D) 인프라 구축과 임상 개발에는 많은 자본 투자가 필요하기 때문에 많은 중소기업에게 장벽이 되고 있습니다. 지질 나노입자, 고분자 나노입자, 리간드 결합 분자 등 새로운 전달 시스템을 통해 전달상의 문제를 극복하기 위한 연구가 진행 중이며, 이는 시장의 성장 기회를 가져올 수 있습니다. 또한, 후기 임상시험에서 RNAi 기반 약물의 유망한 임상 결과도 시장 성장 기회를 가져올 수 있습니다.
본 조사의 주요 특징
- 이 보고서는 각 부문의 잠재적 수익기회를 파악하고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략에 대한 중요한 인사이트를 제공합니다.
- 이 조사는 다음과 같은 매개 변수를 기반으로 세계 RNAi 기술 시장의 주요 기업 프로파일을 작성했습니다. 구체적으로는 기업 하이라이트, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략 등입니다.
- 이 보고서의 내용을 통해 기업의 마케팅 담당자와 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대 및 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있을 것으로 기대됩니다.
- 이 세계 RNAi 기술 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 재무 분석가 등 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 RNAi 기술 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 가정
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 Rnai 기술 시장 : 용도별, 2021-2033년
제5장 세계의 Rnai 기술 시장 : 최종사용자별, 2021-2033년
제6장 세계의 Rnai 기술 시장 : 지역별, 2021-2033년
제7장 경쟁 구도
제8장 애널리스트의 제안
제9장 참고문헌 및 조사 방법
KSM 26.06.17Rnai Technology Market is estimated to be valued at USD 3.58 Bn in 2026 and is expected to reach USD 9.65 Bn by 2033, growing at a compound annual growth rate (CAGR) of 15.2% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 3.58 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 15.20% | 2033 Value Projection: | USD 9.65 Bn |
Global RNAi technology market growth is driven by growing applications of RNA interference technology in therapeutics development and research. RNA interference or RNAi refers to the process of gene silencing mediated by short interfering RNAs (siRNAs) or microRNAs (miRNAs). It has emerged as a powerful tool for selective inhibition of gene expression and functional genomics screens. RNAi holds immense potential for developing novel therapeutics by silencing specific disease-causing genes. The development of safe and effective delivery systems further contributes to the commercialization of RNAi-based therapies. Significant investments in RNAi research and development from biopharma companies and government organizations are resulting in a strong product pipeline.
Market Dynamics
Global RNAi technology market growth is driven by increasing applications of RNAi technology for developing treatments across therapeutic areas. Several drug candidates targeting metabolic, cardiovascular and neurodegenerative disorders are currently under clinical trials. The strong product pipeline and entry of novel RNAi drugs are creating high optimism around the therapeutic potential of this technology. However, technical challenges in RNAi delivery and off-target effects can hamper the market growth. Moreover, requirement of high capital investments for building R&D infrastructure and clinical development deters many small companies. Ongoing research on overcoming the delivery challenges through novel delivery systems such as lipid nanoparticles, polymeric nanoparticles and ligand-conjugated molecules can offer market growth opportunities. Promising clinical outcomes of RNAi-based drugs in late-stage trials can offer market growth opportunities.
Key Features of the Study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global RNAi technology market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Alnylam Pharmaceuticals, OriGene Technologies, Inc., Arrowhead Pharmaceuticals, Dicerna Pharmaceuticals, Silence Therapeutics, Ionis Pharmaceuticals, Merck & Co., Qiagen N.V., Thermo Fisher Scientific, Synlogic, Benitec Biopharma, Gradalis, Sirnaomics, Inc., Marina Biotech, Quark Pharmaceuticals, Regulus Therapeutics, GeneCare Research Institute Co., Ltd., ASC Therapeutics
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- Global RNAi technology market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global RNAi technology market
Market Segmentation
- By Application (Revenue, USD Bn, 2021 - 2033)
- Drug Discovery and Development
- Therapeutics
- Neurology
- Oncology
- Infectious Diseases
- Metabolic Diseases
- Others
- Functional Genomics
- Other
- By End User (Revenue, USD Bn, 2021 - 2033)
- Pharmaceutical & Biotechnology Companies
- Academic & Research Institutes
- CROs & CMOs
- Others
- By Region (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Company Profiles
- Alnylam Pharmaceuticals
- OriGene Technologies, Inc.
- Arrowhead Pharmaceuticals
- Dicerna Pharmaceuticals
- Silence Therapeutics
- Ionis Pharmaceuticals
- Merck & Co.
- Qiagen N.V.
- Thermo Fisher Scientific
- Synlogic
- Benitec Biopharma
- Gradalis
- Sirnaomics, Inc.
- Marina Biotech
- Quark Pharmaceuticals
- Regulus Therapeutics
- GeneCare Research Institute Co., Ltd.
- ASC Therapeutics
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Application
- Market Snapshot, By End User
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Regulatory Scenario
- Acquisitions and Partnerships Scenario
- Funding and Investments
- PEST Analysis
- Porter's Analysis
4. Global RNAi Technology Market, By Application, 2021 - 2033, (USD Bn)
- Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Drug Discovery and Development
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Therapeutics
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Neurology
- Oncology
- Infectious Diseases
- Metabolic Diseases
- Others
- Functional Genomics
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
5. Global RNAi Technology Market, By End User, 2021 - 2033, (USD Bn)
- Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Pharmaceutical & Biotechnology Companies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Academic & Research Institutes
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- CROs & CMOs
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
6. Global RNAi Technology Market, By Region, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Region, 2021-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Bn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033, (USD Bn)
- Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (USD Bn)
- North Africa
- Central Africa
- South Africa
7. Competitive Landscape
- Company Profiles
- Alnylam Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- OriGene Technologies, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Arrowhead Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Dicerna Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Silence Therapeutics
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Ionis Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Merck & Co.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Qiagen N.V.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Thermo Fisher Scientific
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Synlogic
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Benitec Biopharma
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Gradalis
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Sirnaomics, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Marina Biotech
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Quark Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Regulus Therapeutics
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- GeneCare Research Institute Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- ASC Therapeutics
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Alnylam Pharmaceuticals
8. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
9. References and Research Methodology
- References
- Research Methodology
- About Us and Sales Contact
